Liver Tumor Program | NYU Langone Health
Liver Tumor Program specialists at NYU Langone’s Perlmutter Cancer Center provide treatment for liver, biliary tract, and gallbladder tumors.
Local Therapies for Kaposi Sarcoma | NYU Langone Health
NYU Langone doctors may use local therapies to manage a few Kaposi sarcoma lesions on the skin or in the mouth.
Locations Directory | NYU Langone Health
View our directory of NYU Langone locations across the New York City area and in Florida, and find locations by borough and neighborhood.
Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT CJS)
This study seeks to meaningfully address the U.S. opioid epidemic by comparing the effectiveness of two medications used to treat opioid use disorder, extended-release buprenorphine (XR-B) vs. extended-release naltrexone (XR-NTX), among adults currently incarcerated in U.S. jails and prisons at 5 distinct trial sites. This open-label, non-inferiority, head-to-head study design will allow providers, correctional and public health authorities, payers and policy makers' timely and relevant data to assess the effectiveness of XR-B (and XR-NTX) as potentially useful re-entry treatment option. Considering the majority of opioid users leaving jail or prison will inevitably return to their homes and communities untreated and prone to relapse, we believe findings from with important implications for limiting the greater public safety and societal costs of heroin, fentanyl, and prescription opioid addictions. Comparing retention-in-study-medication treatment, we hypothesize XR-B is non-inferior to XR-NTX.
Long-term Cardiac Device Lead Management | NYU Langone Health
NYU Langone electrophysiologists are experienced in safely replacing cardiac device batteries or leads when necessary.
Lower Extremity Arterial Disease | NYU Langone Health
NYU Langone doctors can help you manage the symptoms of lower extremity arterial disease.
LTI-401 An Open-Label Prospective Multicenter Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in Pulmonary Hypertension ASCENT
The purpose of this research study is to evaluate the long-term safety and tolerability of LIQ861 in patients with pulmonary hypertension (elevated pressure in your lungs) associated with interstitial lung disease (PH-ILD), classified by the World Health Organization as Group 3 pulmonary hypertension
Lung Cancer | NYU Langone Health
At NYU Langone’s Perlmutter Cancer Center, our specialists treat non-small cell and small cell lung cancer, and mesothelioma.
Lung Cancer Center | NYU Langone Health
Lung Cancer Center experts at NYU Langone’s Perlmutter Cancer Center provide individualized care for people with lung cancer and mesothelioma.
Lung Cancer Center Leadership | NYU Langone Health
NYU Langone’s Lung Cancer Center is led by a team of experts in lung cancer treatment and research.